FDA Releases Guidance on Evaluating Cardiovascular Risk in New Diabetes Treatments

Summary

The FDA is releasing a new guidance to help pharmaceutical companies assess the cardiovascular risks of new treatments for type 2 diabetes, with the goal of ensuring that these treatments do not increase the risk of heart problems.